Autolus Therapeutics AUTL shares are trading higher on Monday after the company announced the publication of its new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine.
Autolus Therapeutics PLC is a biopharmaceutical company. It's engaged in the development of next-generation programmed T cell therapies for the treatment of cancer.
Autolus Therapeutics shares were trading up 6.70% at $10.25 at the time of publication on Monday. The stock has a 52-week high of $17.19 and a 52-week low of $3.
Cerus CERS shares were trading higher after the company announced that the FDA approved its INTERCEPT blood system for cryoprecipitation.
Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites.
Cerus shares traded higher but were down 0.46% at $6.55 at the time of publication on Monday. The stock has a 52-week high of $7.94 and a 52-week low of $2.71.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
